Argo Biopharmaceutical (Argo Biopharma) has dosed the first subject in its Phase I clinical trial assessing BW-50218, a small-interfering ribonucleic acid (siRNA) therapeutic targeting the transthyretin (TTR) protein.
The study is being conducted in Australia as part of Argo Biopharmaceutical’s ongoing clinical development efforts for next-generation RNA interference (RNAi) therapies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, randomised, single ascending dose, placebo-controlled trial will assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of subcutaneously administered BW-50218 in study participants.
It will also evaluate the safety and biological activity markers to inform the pharmacological profile of BW-50218 and guide future development.
Following this clinical milestone, Argo Biopharmaceutical will receive a milestone payment to support ongoing research and development activities for its hepatic and extra-hepatic siRNA portfolio.
Developed using Argo Biopharmaceutical’s RADS platform, BW-50218 is designed to achieve long-lasting gene silencing through targeted hepatic delivery.
The therapy aims to offer differentiated safety and delivery profiles.
Argo Biopharma co-founder, board chairman, and CEO Dr Dongxu Shu said: “We are pleased to have dosed the first subject in our Phase I trial of BW-50218. We are excited to further our strong collaboration with Novartis, whose dedication to accelerating the development of therapies for patients with unmet medical needs aligns perfectly with our own mission.
“This important milestone underscores the strength of Argo Biopharmaceutical’s expertise in discovery to clinical development and is the seventh molecule from Argo Biopharmaceutical’s platform to progress into clinical testing.”
Argo Biopharmaceutical continues to advance a pipeline of siRNA candidates for cardiovascular and speciality diseases while also progressing earlier-stage extra-hepatic siRNA targets across various tissue types and therapeutic areas.
The company currently has seven RNAi candidates in clinical development for cardiovascular, viral, metabolic, and speciality or rare disease indications.
